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Abstract Amyloidosis prognosis is often related to the
onset of heart failure and a worsening that is concomitant
with kidney–liver dysfunction; thus the Model for End-
stage Liver disease (MELD) may be an ideal instrument to
summarize renal–liver function. Our aim has been to test
the MELD score as a prognostic tool in amyloidosis. We
evaluated 128 patients, 46 with TTR-related amyloidosis
and 82 with AL amyloidosis. All patients had a complete
clinical and echocardiography evaluation; overall biohu-
moral assessment included troponin I, NT-proBNP, crea-
tinine, total bilirubin and INR ratio. The study population
was dichotomized at the 12 cut-off level of MELD scores;
those with MELD score [12 had a lower survival
compared to controls in the study cohort (40.7 vs 66.3 %;
p = 0.006). Either as a continuous and dichotomized
variable, MELD shows its independent prognostic value at
multivariable analysis (HR = 1.199, 95 % CI
1.082–1.329; HR = 2.707, 95 % CI 1.075–6.817, respec-
tively). MELD shows a lower prognostic sensitivity/
specificity ratio than troponin I and NT-proBNP in the
whole study population and AL subgroup, while in TTR
patients MELD has a higher sensitivity/specificity ratio
compared to troponin and NT-proBNP (ROC analysis-
AUC: 0.853 vs 0.726 vs 0.659). MELD is able to predict
prognosis in amyloidosis. A MELD score [12 selects a
subgroup of patients with a higher risk of death. The pre-
dictive accuracy seems to be more evident in TTR patients
in whom currently no effective scoring systems have been
validated.
Keywords Amyloid  Prognosis  MELD  Liver
dysfunction
Introduction
Different risk scores, biohumoral and clinical variables
have been evaluated as predictors of prognosis in patients
affected by amyloidosis [1–4]. The majority of them are
focused on the cardiovascular system, such as atrial pep-
tides [5, 6], troponin [6, 7] and echocardiographic indexes
of left and right ventricular function [8–12]. They inde-
pendently predict the prognosis of this systemic infiltrative
multi-organ disease.
The progression and worsening of amyloidosis is due to
the onset of heart failure [13], often associated with kidney
or liver dysfunction; thus the composite Model for End-
stage Liver disease (MELD) [14], based on patient’s level
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of creatinine, total bilirubin and International Normalized
Ratio-INR, may be an useful instrument to summarize the
global renal and liver function.
The MELD scoring system usually adopted for priori-
tizing cirrhotic patients candidates for liver transplantation
[15] has been recently demonstrated to predict the prog-
nosis in outpatients with heart failure [16], in those can-
didates for ventricular assistance devices [17, 18], or to
tricuspid valve surgery or orthotopic heart transplantation
[19–21].
In amyloidosis patients, the kidney and liver dysfunction
may be caused by different mechanisms, in part linked to
the direct infiltrative deposition of amyloid mostly in AL
forms, and the rest to the onset of cardio-hepatic [22] or
cardio-renal syndromes [23] associated with the presence
of heart failure. The aforementioned syndromes are usually
characterized by the contemporary presence of venous
congestion and arterial hypoperfusion; both the hemody-
namic alterations are related to the presence of cardiac
biventricular dysfunction [23].
In this context, we have already demonstrated the
prognostic role of right ventricular dysfunction in patients
with AL amyloidosis [12, 24]; however, the pathophysio-
logical pathway is not fully understood. There may be a
possible link in the progressive worsening of renal and
liver function.
On this basis our aims have been to demonstrate, first,
the predictability of the MELD score in amyloidosis
patients, and second to test if its prognostic value is
influenced by the etiology of the amyloidosis.
Methods
Data collection
From the database of Regional Center of Amyloidosis of
the University of Florence, Italy, between January 2006
and June 2013, we retrospectively evaluated 154 patients
referred to our amyloidosis referral center for clinical and
instrumental evaluation. One patient was excluded because
he was already on dialysis; five excluded patients were on
anticoagulant therapy with warfarin at the entry visit due to
atrial fibrillation; moreover in 16 patients one or more of
the MELD variables were unavailable at diagnosis; and in
four patients biohumoral variable analysis exceeded the
30-day temporal window from echocardiography evalua-
tion. The study population was therefore composed of 128
patients, 46 with TTR-related amyloidosis (28 with ATTR
wild type and 18 with ATTR mutated) and 82 with AL
amyloidosis. Diagnosis of AL amyloidosis was made by
biopsy of an involved organ, which demonstrated the typ-
ical Congo red birefringence when viewed under polarized
light. The positive biopsy site was abdominal fat in 53
patients (65 %), kidney in 12 (14 %), myocardium in 12
(14 %), and salivary gland in 5 (7 %). AL amyloidosis was
confirmed by the finding of a monoclonal protein in the
serum or urine or a monoclonal population of plasma cells
in the bone marrow, when evaluated by immunohisto-
chemistry in the absence of any TTR mutation at DNA
analysis. In two cases with solitary myocardial involve-
ment, electron microscopy with immunogold labeling was
used to unambiguously characterize amyloid fibrils.
Diagnosis of ATTR mutated was based on genotyping
[25], and tissue biopsy of abdominal fat in 10 patients
(56 %), myocardium in 5 (28 %), and salivary gland in 3
(16 %). ATTR mutations were: Ile68Leu (n = 11 patients,
61 %), Val122Ile (n = 5 patients 28 %), Glu54Val (n = 1
patients), Gly57Arg (n = 1 patients). All 18 of the patients
showed the characteristic increased myocardial uptake of
99mTc-3,3-diphosphono-1,2-propanodicarboxylic (DPD)
acid scintigraphy, further confirming the diagnosis of TTR-
related cardiac amyloidosis [26].
Diagnosis of ATTR wild type was made by tissue
biopsy or positive DPD scintigraphy in absence of TTR
mutation and of a plasma cell dyscrasia. A total of 19
patients (68 %) had histological proof of ATTR amyloi-
dosis by Congo red and immunohistochemical staining of
myocardial (n = 6, 31 %) or other tissues (n = 13; 69 %;
abdominal fat in 6 patients, carpal tunnel biopsy in 4, and
salivary gland in 3). In 9 patients (32 %) with negative
tissue biopsy, definite cardiac ATTR wild type was defined
as intense 99mTc-DPD uptake in heart (grade 2 or 3 as
defined by Perugini et al.) [26] in the absence of a plasma
cell dyscrasia and TTR/AApoAI mutation; in the latter
patients a cardiac MRI was performed with a late
gadolinium enhancement (LGE) consistent with cardiac
amyloid involvement.
All patients gave written informed consent for their
clinical records to be used for research purposes, in
accordance with Institutional Review Board guidelines.
NT-proBNP was measured with an electrochemilumi-
nescence sandwich immunoassay (ECLIA, Roche) in the
central hospital laboratory. Troponin I measurements were
performed by immunochemiluminescence assay using a
Centaur XP (Siemens Healthcare, Erlangen, Germany).
Creatinine, total bilirubin and International Normalized
Ratio were collected from central hospital laboratory. Both
systolic and diastolic arterial blood pressure were evaluated
at the entry visit in the Registry.
Standard and TDI echocardiography
In a temporal window of 30 days from biohumoral analy-
sis, patients were referred to our laboratory for M-mode,
2-dimensional, conventional and tissue Doppler
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echocardiographic study. Echocardiography was performed
by a single experienced operator (FC), blinded to the
clinical history of the patient, using a Vivid 7 System
(Vingmed, General Electric, Horten, Norway) equipped
with a 3S probe. At least three consecutive beats were
recorded, and the images were digitized and analyzed off-
line. According to the standards of the American Society of
Echocardiography [27] the following parameters were
assessed: end-diastolic thickness of ventricular septum
(IVS) and LV posterior wall (PW), LV end-diastolic and
end-systolic diameters (LV EDD and LV ESD, respec-
tively), body surface area (BSA)-indexed LV mass (LV-
massind), LV endocardial fractional shortening (FS), left
atrial area (LAA, evaluated from the apical four chamber
view at the end of systole), LV end-diastolic and end-
systolic volumes (LV EDV and LV ESV, respectively),
ejection fraction (EF, estimated with the biplane Simpson
method), mitral peak flow velocity in early and late diastole
(E and A, respectively, during atrial contraction), E wave
deceleration time (DT), E/A ratio, RV free wall thickness
(RV FW), RV end-diastolic diameter (RV EDD, evaluated
from parasternal long axis view) and the systolic dis-
placement of the lateral portion of the tricuspid annular
plane (TAPSE).
Pulmonary artery systolic pressure (PASP) was
approximated by adding to trans-tricuspid pressure gradient
an estimate of right atrial pressure assessed by inferior vena
cava dimension and respiratory variation. We also evalu-
ated pulsed TDI-derived early diastolic peak velocity at
lateral mitral annulus (E’), as an index of LV relaxation,
and E/E’ ratio, as an index of LV filling pressure.
MELD scoring system
The standard MELD score was defined according to the
following equation: 11.2 9 (Ln INR) ? 0.378 9 (Ln total
bilirubin) ? 0.957 9 (Ln creatinine) ? 0.643 [14].
Statistical analysis
Our analyses were performed by using the SPSS for
Windows package version 19 (SPSS Inc., Chicago, IL,
USA). Categorical and continuous variables were expres-
sed as frequencies (percentages) and as mean ± standard
deviation, respectively. Categorical comparisons were used
for comparison between groups. The cut-off level of
MELD was pointed out at 12 according to Kim MS and
colleagues data [16].
The sensitivity and specificity of this predefined cutoff
in all-cause death prediction was tested using area under
the receiver operating characteristics curve (ROC) analysis
in whole study population and subgroups of patient
according to amyloid etiology. We calculated the area
under the curve of MELD comparing it with AUC of NT-
proBNP that we know to be the strongest predictor of
prognosis in amyloidosis [13].
The survival rate of the two MELD scoring groups was
compared by using Kaplan–Meier curves with a log-rank
test in the whole population and subgroups of patient
according to amyloid etiology.
Two different models of Cox proportional hazard anal-
ysis were used to verify the association of MELD cutoff
and MELD as an ordinal variable. In the multivariable
model we introduced those variables associated with out-
come in univariate analysis and those we considered rele-
vant according to literature [13]. Among variables that had
a predictive value on mortality at univariate analysis, but
with similar clinical significance, only one was introduced
in the multivariate logistic regression model, to avoid co-
linearity.
For all analyses the p value was pointed out at \0.05,
the INPUT was 0.05 and the OUTPUT was 0.10 for all
multivariable Cox regression models.
Results
Our study population was composed of 128 patients
including 82 patients with systemic AL amyloidosis and 46
patients with TTR-related amyloidosis (28 with ATTR
wild type and 18 with ATTR mutated).
The mean age of the study population was 71 years, 78
(60 %) were males, mean ejection fraction was
55.1 ± 11.1 %, 46 (35.9 %) were in advanced (III-IV)
NYHA class, the mean level of creatinine, bilirubin and
INR were 1.18 ± 0.50 mg/dl, 0.82 ± 0.50 mg/dl,
1.14 ± 1.03, respectively. The mean MELD score was
10.1 ± 3.7. Our population presented significant diastolic
dysfunction assessed by E’ and E/E’ 5.3 ± 1.9 cm/sec and
16.4 ± 7.3, respectively. The indirect index of right ven-
tricular function TAPSE was 18.4 ± 4.6.
Mean follow-up period was 22.2 ± 20.0 months; during
this follow-up period we registered 50 deaths (39 %), one
patient with ATTR mutated etiology died from a cerebral
neoplasm, one patient with AL amyloidosis died from end-
stage renal failure, all other patients died from a cardio-
vascular reason (end-stage heart failure or sudden death).
Thus the mortality outcome can be defined substantially as
cardiovascular mortality.
Univariate analysis
The study population was dichotomized according to the
12 cut-off level of MELD and 28 patients (20 %) were in
the group above the cut-off level (Table 1). Comparisons
between groups revealed that patients with a higher MELD
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show increased LV mass and LA area, lower LV EF and
worse LV diastolic function. Moreover, they demonstrate
RV longitudinal dysfunction with an increase in pulmonary
artery systolic pressure. On the other hand, no significant
difference is observed in RV dimension and wall thickness.
Patients with MELD [12 are significantly older with
increased NT-proBNP plasma level while no significant
differences are observed in troponin values. Gender dis-
tribution and arterial blood pressure values are superim-
posable between the two groups. The prevalence of a
history of diabetes mellitus, arterial hypertension, coronary
artery disease and peripheral artery disease does not differ
between the groups. The baseline characteristics of our
cohort are further categorized according to amyloidosis
etiology (Table 1).
We observe fewer baseline differences between the
dichotomized group in AL amyloidosis patients. In this
subgroup, patients with a MELD score [12 present an
increase in NT-proBNP plasma levels and increased
RVEDD while no differences are observed in LV dimen-
sions and function, TAPSE or PASP. On the other hand, in
the TTR population, subjects with a MELD [12 show
Table 1 Demographic, clinical, biohumoral and echocardiographic characteristics of the study population and in the two etiologies of amy-
loidosis according to MELD cutoff















Gender (m/f) 61/39 17/11 0.900 35/34 5/8 0.470 26/5 12/3 0.740
Age years 69.7 ± 10.8 75.3 ± 8.5 0.013 68.2 ± 10.3 71.3 ± 7.7 0.483 73.3 ± 11.4 78.7 ± 6.1 0.060
Creatinine mg/
dl
1.01 ± 0.30 1.80 ± 0.59 \0.001 1.04 ± 0.34 2.1 ± 0.71 \0.001 0.95 ± 0.2 1.52 ± 0.33 \0.001
Bilirubin mg/dl 0.73 ± 0.40 1.10 ± 0.67 0.003 0.61 ± 0.24 1.01 ± 0.83 0.002 1.00 ± 0.53 1.31 ± 0.51 0.077
INR 1.08 ± 0.14 1.39 ± 0.44 0.001 1.04 ± 0.13 1.16 ± 0.20 0.014 1.14 ± 0.14 1.59 ± 0.50 0.005
Nt-proBNP ng/l 4252 ± 6301 9488 ± 1147 0.023 4637 ± 4637 11426 ± 14951 0.002 3364 ± 4874 6524 ± 4381 0.040
Troponin ng/l 0.16 ± 0.31 0.20 ± 0.21 0.549 0.16 ± 0.34 0.19 ± 0.30 0.545 0.17 ± 0.18 0.18 ± 0.10 0.852
SBP mm Hg 119.1 ± 17.9 126.5 ± 13.1 0.305 114.7 ± 17.3 108.6 ± 16.5 0.753 122 ± 18 126 ± 13 0.589
DBP mm Hg 70 ± 10.8 74.3 ± 8.2 0.316 70.6 ± 11.7 69.5 ± 11.3 0.872 69 ± 10 74 ± 8 0.298
BSA m2 1.74 ± 0.15 1.74 ± 0.14 0.940 1.7 ± 0.14 1.69 ± 0.16 0.543 1.79 ± 0.16 1.77 ± 0.11 0.793
LVDD mm 45.6 ± 5.9 45.3 ± 4.8 0.770 45.3 ± 5.7 43.8 ± 5.8 0.404 46.3 ± 6.4 46.4 ± 3.6 0.962
LVSD mm 29.7 ± 6.4 31.4 ± 6.4 0.239 28.1 ± 5.5 28.2 ± 5.5 0.945 33.2 ± 6.7 34.1 ± 5.9 0.690
FS % 34.8 ± 9.5 30.7 ± 10.6 0.060 37.9 ± 8.5 35.7 ± 10.5 0.456 27.9 ± 7.9 26.7 ± 9.1 0.673
IVS mm 14.5 ± 3.6 15.9 ± 3.3 0.067 13.2 ± 3.2 14.5 ± 3.6 0.216 17.6 ± 2.6 17.1 ± 2.6 0.543
LVPW mm 13.9 ± 3.0 15.6 ± 2.9 0.009 12.9 ± 2.8 14.5 ± 3.9 0.092 16.0 ± 2.1 16.4 ± 1.6 0.530
LVmass I g/m2 153.1 ± 52.9 178.1 ± 51.1 0.032 135.2 ± 44.9 151.0 ± 43.0 0.261 195.5 ± 46.3 199.7 ± 47.6 0.953
LA area cm2 22.6 ± 5.5 25.6 ± 5.1 0.014 21.2 ± 4.9 22.9 ± 4.5 0.270 26.0 ± 5.3 28.0 ± 4.3 0.242
LVEDV ml 83.9 ± 25.2 84.7 ± 17.8 0.891 82.6 ± 24.4 77.4 ± 17.1 0.484 87.0 ± 27.2 90.5 ± 16.6 0.653
LVESV ml 37.2 ± 17.4 42.9 ± 17.8 0.143 34.2 ± 14.4 33.5 ± 11.0 0.873 44.0 ± 21.6 50.5 ± 20.2 0. 343
EF % 56.3 ± 10.0 50.7 ± 13.7 0.020 58.6 ± 8.4 56.9 ± 10.8 0.549 51.1 ± 11.5 45.7 ± 14.1 0.177
E/A 1.56 ± 1.03 1.70 ± 0.82 0.566 1.35 ± 0.89 1.32 ± 0.70 0.921 2.2 ± 1.1 2.2 ± 0.67 0.785
DT ms 200 ± 73 176 ± 74 0.152 209 ± 69 198 ± 107 0.674 181 ± 79 159 ± 26 0.320
E0 cm/s 5.5 ± 2.0 4.6 ± 1.4 0.055 5.8 ± 2.1 5.1 ± 1.6 0.321 4.8 ± 1.7 4.2 ± 1.0 0.232
E/e0 15.6 ± 7.1 19.4 ± 7.1 0.020 14.6 ± 7.6 16.2 ± 5.5 0.493 18.1 ± 5.3 22.2 ± 7.4 0.047
RVFW mm 7.4 ± 1.7 7.8 ± 1.7 0.254 6.8 ± 1.5 7.1 ± 1.9 0.692 8.5 ± 1.7 8.4 ± 1.2 0.894
RVEDD mm 29.1 ± 5.4 29.7 ± 6.5 0.622 28.7 ± 4.9 25.3 ± 4.5 0.034 30.0 ± 6.2 33.5 ± 5.7 0.088
TAPSE mm 18.9 ± 4.3 16.7 ± 5.5 0.030 19.6 ± 4.3 19.2 ± 6.8 0.772 17.1 ± 3.5 14.6 ± 3.0 0.031
PASP mmHg 34.3 ± 11.2 39.7 ± 11.6 0.037 33.2 ± 11.8 35.3 ± 10.2 0.581 37.0 ± 9.2 42.9 ± 11.9 0.097
A late diastolic mitral peak flow velocity, E early diastolic mitral peak flow velocity, e0 early diastolic peak velocity at lateral mitral annulus, FS
fractional shortening, EF ejection fraction, IVS interventricular septum thickness, LA left atrium, LV left ventricular, LVEDD LV end-diastolic
diameter, LVEDV LV end-diastolic volume, LVESD LV end-systolic diameter, LVESV LV end-systolic volume, LVPW posterior wall thickness,
PASP pulmonary artery systolic pressure, RV right ventricular, RVEDD RV end-diastolic diameter, RVFW RV free wall thickness, TAPSE
tricuspid annulus systolic plane excursion
26 Intern Emerg Med (2017) 12:23–30
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increased LV filling pressure assessed by E/e’ ratio with
increase PASP and reduce RV function.
Prognostic findings
As reported in Table 2, deceased patients show increased
MELD (11.5 ± 4.6 vs 9.1 ± 2.7, p\ 0.001) and present a
worse clinical, biohumoral and echocardiographic profile
(Table 2). Results of the unadjusted Kaplan–Meier analysis
comparing survival of patients according to dichotomized
MELD in the whole population and according to amyloid
etiology are reported in the ESM Figs. 1 and 2. As visually
evident, the two curves split early according to MELD
cutoff with a significant divergence in overall study pop-
ulation and in the two etiology cohorts. Moreover, it is
notable as the survival falls rapidly both in AL and TTR
patients. At the end of the follow-up in the whole study
cohort the MELD [12 patients have a significantly lower
survival compared to other patients (40.7 vs 66.3 %), as
well as in the two etiology cohorts (AL cohort: 30.8 vs
59.7 %; TTR cohort: 50.0 vs 80.6 %).
The ROC survival results of MELD score, NT-proBNP
and troponin for whole population and amyloidosis eti-
ologies are reassessed in Table 3. MELD AUC is inferior
to NT-proBNP and troponin AUC in the whole population
and in AL patients; conversely in TTR subjects, the MELD
score reaches a large AUC compared to other variables
with NT-proBNP obtaining the worst result.
Univariate and multivariate analysis
At univariate analysis, several variables are significantly
related to survival, i.e., NYHA class p\ 0.0001; troponin
p\ 0.0001, NT-proBNP \0.001, LV mass BSA indexed
p\ 0.028, TAPSE p\ 0.0001, LV EF p\ 0.002, E/e’
p\ 0.0001, MELD as dichotomous variable p\ 0.008 and
MELD as continuous variable p\ 0.0001.
In Table 4 we report the results of the two different Cox
regression multivariate analysis models in which MELD
entered as continuous parameter (model 1) and dichoto-
mous one (model 2), respectively. In both models, the
MELD scores have an independent predictive power after
adjustment of overall well-known variables able to influ-
ence the prognosis in amyloidosis.
Discussion
This study demonstrates that the MELD scoring system is
able to predict prognosis in patients with amyloidosis. Our
data show that a MELD score [12 selects a high-risk
subgroup of amyloidosis patients with poor prognosis
during the follow-up with a independent risk of 2.7-fold
higher compared to the subgroup with MELD B12. Inter-
estingly, for each point of increase of MELD score at
baseline, the risk of death rises 19.9 % in the follow-up.
Our finding is in accordance with the results of Kim and
colleagues [16] that highlight the prognostic role of MELD
in heart failure patients. In fact they demonstrate that a
MELD scoring system above 12 is independently associ-
ated with 10 % excess of risk for heart transplantation in
ambulatory patients with heart failure.
This parallelism may be due to the fact that the onset
and the worsening of heart failure are often final cause of
death in amyloidosis patients [13]. Furthermore, we know
how heart failure is a systemic disease and not simply a
cardiovascular disease [28] in which a key prognostic point
is related to the onset of cardio-hepatic or cardio-renal
syndromes [22, 23]. On this basis, the MELD scoring
system is an easy and rapid instrument that can be used in
the risk stratification of amyloidosis patients; moreover, the
combination of the MELD score and cardiovascular
Table 2 Differences in clinical, biohumoral and echocardiographic
characteristics between dead or alive patients
Alive (n = 78) Dead (n = 50) p
MELD 9.1 ± 2.7 11.5 ± 4.6 \0.001
Age (years) 71.8 ± 10.6 69.7 ± 10.5 0.289
Gender M/F 50/28 22/28 0.352
Etiology (AL-TTR) 45/33 37/13 0.061
NYHA class
I 34 9
II 28 11 \0.001
III 16 19
IV 0 11
NT-proBNP ng/l 2625 ± 3151 9519 ± 10897 \0.001
Troponin ng/l 0.10 ± 0.12 0.28 ± 0.42 0.006
Creatinine mg/dl 1.1 ± 0.4 1.34 ± 0.5 0.070
LVmass g/m2 154.9 ± 57.2 165.8 ± 51.1 0.251
LA area cm2 22.4 ± 5.6 24.1 ± 4.5 0.062
E/e0 15.2 ± 6.4 18.2 ± 8.1 0.002
DT ms 200 ± 73 186 ± 75 0.302
LVEDD mm 46.7 ± 5.5 43.6 ± 5.2 0.002
LVESD mm 30.3 ± 6.4 29.9 ± 5.9 0.637
LVEDV ml 88.1 ± 25.4 77.8 ± 20.5 0.010
LVESV ml 39.2 ± 18.1 37.3.4 ± 17.6 0.572
EF % 56.4 ± 9.8 52.6 ± 12.4 0.041
TAPSE mm 19.5 ± 3.9 16.4 ± 5.2 \0.001
PASP mmHg 33.5 ± 11.4 39.7 ± 10.8 0.003
E early diastolic mitral peak flow velocity, e0 early diastolic peak
velocity at lateral mitral annulus, EF ejection fraction, LA left atrium,
LV left ventricular, LVEDD LV end-diastolic diameter, LVEDV LV
end-diastolic volume, LVESD LV end-systolic diameter, LVESV LV
end-systolic volume, PASP pulmonary artery systolic pressure,
TAPSE tricuspid annulus systolic plane excursion
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variables, exploring different clinical domains, might give
significant additive prognostic information in these
patients.
Another important result is related to the finding that for
each point of increase of MELD, the patient risk of death
rises significantly; this result may open an interesting
perspective for MELD scoring system in the managing of
amyloidosis patients. In fact as demonstrated in cirrhotic
patients, the MELD scoring system might be used to con-
tinuously evaluate the amyloidosis patients in the follow-
up visits with the aim of capturing an early significant
modification of the liver and renal global functions with the
same prognostic perspective that we often attribute to the
self-reported cardiovascular functional evaluation descri-
bed with the NYHA classification.
Furthermore, as described by ROC curve analysis, the
MELD scores, although always statistically significant,
show a lower sensitivity/specificity ratio than those of
troponin I and NT-proBNP in the whole study population
and AL subgroup. Conversely, in TTR subgroup of
patients, the MELD scores seem to have the larger AUC
compared to Troponin and NT-proBNP. It is notable that
the MELD scores reach the best accuracy in survival pre-
diction in a TTR patient in whom currently no effective
scoring systems have been validated.
These best results in the TTR cohort could be due to the
fact that no clinical significant liver or kidney infiltration is
detectable in TTR amyloidosis, therefore it could be
hypothesized that in a TTR patient, the MELD score cap-
tures the worsening of liver and kidney function specifi-
cally due to the heart failure pathophysiological cascade
related to cardio-renal or cardio-hepatic syndrome.
In AL amyloidosis, a MELD score increase, related
mainly to rise in creatinine value could reflect a
parenchymal kidney injury, and not be a marker of car-
diorenal syndrome or glomerular venous congestion [23].
In fact no significant correlation is observed in AL patients
between MELD scores and right ventricular function or
pulmonary pressure (TAPSE and PASP, respectively,
Table 5 in Appendix data). Conversely in TTR patients, we
Table 3 Receiver operating characteristics (ROC) analysis of MELD, troponin and NT-proBNP in study population and in the two amyloidosis
etiologies
All population AL amyloidosis TTR amyloidosis
AUC (CI) p AUC (CI) p AUC (CI) p
MELD 0.647 (0.536–0.758) 0.012 0.650 (0.497–0.763) 0.041 0.853 (0.717–0.989) 0.002
NT-proBNP 0.710 (0.604–0.816) \0.001 0.749 (0.628–0.870) \0.001 0.659 (0.449–0.868) 0.658
Troponin 0.682 (0.576–0.788) 0.002 0.716 (0.592–0.839) 0.002 0.726 (0.546–0.907) 0.044
Table 4 Independent predictors of survival in the study population using MELD variable as continuous (MODEL 1) and dichotomous (MODEL
2)
Model 1 Model 2
B ± SE p HR (95 %CI) B ± SE p HR (95 %CI)
Gender 0.63 ± 0.51 0.217 1.437; (0.831–2.254) 0.30 ± 0.25 0.234 1.349; (0.824–2.208)
Age 0.01 ± 0.02 0.959 1.001; (0.959–1.045) -0.01 ± 0.20 0.830 0.996; (0.957–1.030)
NYHA class -3.46 ± 0.98 \0.001 0.040; (0.005–0.215) -2.96 ± 0.96 0.002 0.052; (0.008–0.338)
NT_proBNP 0.00 ± 0.00 0.088 1.000; (1.000–1.000) 0.00 ± 0.00 0.025 1.000; (1.000–1.000)
Troponin 0.14 ± 1.04 0.894 1.150; (0.149–8.889) -0.09 ± 1.05 0.930 0.913; (0.118–7.081)
LVmass -0.01 ± 0.01 0.471 0.995; (0.981–1.009) -0.01 ± 0.01 0.282 0.993; (0.980–1.006)
EF % -0.05 ± 0.02 0.016 0.955; (0.919–0.991) -0.05 ± 0.02 0.011 0.951; (0.916–0.988)
E/e0 0.01 ± 0.04 0.892 1.005; (0.938–1.076) 0.00 ± 0.03 0.981 1.001; (0.938–1.068)
TAPSE mm 0.04 ± 0.07 0.549 1.040; (0.915–1.181) 0.02 ± 0.06 0.813 1.015; (0.899–1.145)
AL vs TTR -0.81 ± 0.79 0.303 0.444; (0.095–2.078) -0.52 ± 0.72 0.471 0.594; (0.144–2.449)
MELDa 0.18 ± 0.05 0.001 1.199; (1.082–1.329)
MELD[ 12 1.00 ± 0.47 0.035 2.707; (1.075–6.817)
E early diastolic mitral peak flow velocity, e0 early diastolic peak velocity at lateral mitral annulus, EF ejection fraction, MELD model for end-
stage liver disease, TAPSE tricuspid annulus systolic plane excursion
a Considered as continuous variable
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find a strong bivariate correlation between MELD and
TAPSE/PASP (Additional supplement Table).
Limitation
This paper reflects the limitations pertaining to retrospec-
tive analysis, therefore MELD scores need to be validated
in a longitudinal prospective study prior to being consid-
ered for clinical practice.
Our choice to put together ATTRm and ATTRwt
patients might be criticized. However, in our population the
TTRm and TTRwt phenotypes were similar in cardiac
involvement, echocardiographic profile and age at diag-
nosis [20, 29–31]. A further limitation is lack of biopsy
evidence of amyloid in 32 % of TTRwt population. How-
ever, this cohort of patients was fully characterized with all
other clinical investigative techniques currently available.
When combined these are known to provide high diag-
nostic accuracy [32, 33].
Conclusion
Our study demonstrated that MELD scoring system is able to
predict prognosis in patients with amyloidosis. Our data show
that MELD has a lower sensitivity/specificity ratio in survival
prediction than those of troponin I and NT-proBNP in whole
study population and AL subgroup. On the other hand, it is
notable that MELD reaches the best accuracy in survival
prediction in TTR patients, a subgroup in whom currently no
effective scoring systems have been validated.
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